Content
March 2010, Volume 8, Issue 2
- 75-88 Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?
by Paul Farnham - 89-97 Health system choice
by Paul Scuffham & Jennifer Whitty & Matthew Taylor & Ruth Saxby - 99-109 Willingness to pay for maternal health outcomes
by Laura Ternent & Paul McNamee & David Newlands & Danielle Belemsaga & Adjima Gbangou & Suzanne Cross - 111-118 Outpatient medication costs of patients with cystic fibrosis in Germany
by Daniela Eidt-Koch & Thomas Wagner & Thomas Mittendorf & J.-Matthias Schulenburg - 119-128 Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy
by Lorenzo Pradelli & Sergio Iannazzo & Orietta Zaniolo & Paola Botrugno - 129-140 Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder
by Regina Rendas-Baum & Min Yang & Joseph Gricar & Gene Wallenstein
December 2009, Volume 7, Issue 4
- 209-217 Which barriers prevent the efficient use of resources in medical device sectors?
by Steven Simoens - 219-224 Assessing comparative effectiveness research in the US
by Joshua Cohen & John Bridges - 225-227 Cost effectiveness of antiretrovirals — long term or short term?
by Steffen Flessa - 229-243 The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda
by Elliot Marseille & James Kahn & Christian Pitter & Rebecca Bunnell & William Epalatai & Emmanuel Jawe & Willy Were & Jonathan Mermin - 245-254 A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine
by Derek Misurski & Maureen Lage & Rosalind Fabunmi & Kristina Boye - 255-264 Cost savings associated with filling a 3-month supply of prescription medicines
by Atonu Rabbani & G. Alexander - 265-277 Demand for outpatient healthcare
by Sisira Sarma
September 2009, Volume 7, Issue 3
- 137-147 Soft regulations in pharmaceutical policy making
by Björn Wettermark & Brian Godman & Bengt Jacobsson & Flora Haaijer-Ruskamp - 149-154 Value-based insurance design in medicare
by William Encinosa - 155-165 Financial risk of the Biotech Industry versus the Pharmaceutical Industry
by Joseph Golec & John Vernon - 167-180 Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden
by Ivar Kristiansen & Kerstin Bingefors & Dag Nyholm & Dag Isacson - 181-191 Economic evaluation of Sinfrontal®in the treatment of acute maxillary sinusitis in adults
by Kyra Kneis & Afschin Gandjour - 193-205 The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
by Zhimei Liu & Quan Doan & Jennifer Malin & Robert Leonar
June 2009, Volume 7, Issue 2
- 71-89 Implementing differential pricing for essential medicines via country-specific bilateral negotiated discounts
by Ebenezer Tetteh - 91-108 Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
by Stephanie Earnshaw & Jonathan Graham & MerriKay Oleen-Burkey & Jane Castelli-Haley & Kenneth Johnson - 109-119 Comparative utility of aripiprazole and haloperidol in schizophrenia
by John Kane & Edward Kim & Hong Kan & Zhenchao Guo & John Bates & Richard Whitehead & Andrei Pikalov - 121-136 Aversion to geographic inequality and geographic variation in preferences in the context of healthcare
by Carlota Quintal
March 2009, Volume 7, Issue 1
- 1-9 Informing disinvestment through cost-effectiveness modelling
by Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith - 11-17 Health-promoting schools
by Albert Lee - 19-29 Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction
by Florence Canoui-Poitrine & Grégoire Jeanblanc & Corinne Alberti & Priscilla Armoogum & Ana Cebrian & Didier Carrié & Patrick Henry & Emmanuel Teiger & Michel Slama & Christian Spaulding & Isabelle Durand-Zaleski - 31-41 Direct economic burden of high-risk and metastatic melanoma in the elderly
by Keith Davis & Debanjali Mitra & Srividya Kotapati & Ramy Ibrahim & Jedd Wolchok - 43-59 Oral therapies for the treatment of pulmonary arterial hypertension
by George Dranitsaris & Sanjay Mehta - 61-70 Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
by Alan White & Howard Birnbaum & Dov Rothman & Nathaniel Katz
October 2008, Volume 6, Issue 4
- 217-230 Does extending health insurance coverage to the uninsured improve population health outcomes?
by James Thornton & Jennifer Rice - 231-246 Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B
by Elizabeth Arnold & Yong Yuan & Uchenna Iloeje & Greg Cook
July 2008, Volume 6, Issue 2
- 81-92 The impact of banning smoking in workplaces
by Shane Allwright - 93-102 The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand
by Edward Norey & Tessa Simone & Shaker Mousa - 103-112 Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting
by Elise Pelletier & Paula Smith & Kristina Boye & Derek Misurski & Sandra Tunis & Michael Minshall - 113-135 Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women
by Dirk Mueller & Afschin Gandjour - 137-144 Households’ willingness to pay for a motorcycle helmet in Hanoi, Vietnam
by Khanh Pham & Quynh Thi & Dennis Petrie & Jon Adams & Christopher Doran - 145-155 The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care
by Edward Gardner & Moises Maravi & Cornelis Rietmeijer & Arthur Davidson & William Burman - 157-162 Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure
by Joseph Menzin & Luke Boulanger & Simon Tang & Kamlesh Thakker & Steven Nissen